| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4375426 | A | Oral bioavailability in mouse at 10 mg/kg by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 2. | ALA4375427 | A | Tmax in mouse at 10 mg/kg, po by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 3. | ALA4375428 | A | Tmax in mouse at 10 mg/kg, ip by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 4. | ALA4375429 | A | Cmax in mouse at 10 mg/kg, ip by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 5. | ALA4375431 | A | Cmax in mouse at 10 mg/kg, po by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 6. | ALA4375438 | T | Toxicity in CD-1 mouse assessed as effect on stool weight at 10 mg/kg, po administered via gavage for 1 hr | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 7. | ALA4375439 | B | Inhibition of mouse slc26a3 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay | Mus musculus | 45 | cell-based format | Scientific Literature | ||
| 8. | ALA4375440 | B | Inhibition of mouse slc26a3 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/bicarbonate exchange by measuring decrease in cytoplasmic alkalinization by BCECF probe-based fluorescence assay | Mus musculus | 2 | cell-based format | Scientific Literature | ||
| 9. | ALA4375441 | B | Inhibition of mouse slc26a4 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay | Mus musculus | 2 | cell-based format | Scientific Literature | ||
| 10. | ALA4375442 | B | Inhibition of mouse slc26a6 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay | Mus musculus | 2 | cell-based format | Scientific Literature | ||
| 11. | ALA4375443 | B | Inhibition of human slc26a9 expressed in FRT cells co-expressing EYFP-H148Q/I152L/F46L assessed as reduction in protein-mediated chloride/iodide exchange at 10 uM preincubated for 10 mins followed by NaI-substituted PBS addition and measured by YFP-based fluorescence assay | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 12. | ALA4375446 | A | Drug level in mouse serum at 10 mg/kg, po or ip measured after 72 hrs by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 13. | ALA4375449 | F | Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in stool weight at 3 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4375450 | F | Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in fecal pellet number at 3 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 15. | ALA4375451 | F | Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as improvement in stool water content at 3 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA4375452 | T | Toxicity in CD-1 mouse assessed as effect on fecal pellet number at 10 mg/kg, po administered via gavage for 1 hr | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 17. | ALA4375453 | T | Toxicity in CD-1 mouse assessed as effect on stool water content at 10 mg/kg, po administered via gavage for 1 hr | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 18. | ALA4375454 | F | Anti-absorptive activity in loperamide-induced CD-1 mouse model of constipation assessed as stool hydration at 1 mg/kg, po administered via gavage for 1 hr prior to loperamide challenge and measured after 3 hrs relative to control | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4375455 | A | AUC in mouse at 10 mg/kg, po by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA4375456 | A | AUC in mouse at 10 mg/kg, ip by LC-MS analysis | Mus musculus | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!